Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $40M Series C (Mar 2026) led by Quadrille Capital and General Catalyst. $95M+ total. 4x revenue growth 2025. 130%+ NRR. Clients: Mount Sinai, Baptist Health, AdventHealth.
Adonis is an AI-powered healthcare revenue cycle management (RCM) platform targeting the surging hospital denial crisis: payer denials are now the primary driver of healthcare revenue risk, with denial rates increasing year-over-year as commercial payers deploy more aggressive prior authorization and claims review protocols. The company raised $40 million in Series C financing in March 2026 led by Quadrille Capital and General Catalyst, bringing total funding to $95 million+ on the back of 4x revenue growth in 2025.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.